Cell Culture Media Additives

A vinyl polymer-based cell culture medium additive enhances the expression and activity of drug metabolism-related molecules, addressing the limitations of current methods by improving enzyme activity and reducing cytotoxicity, thereby supporting accurate drug screening and stable supply for drug development.

JP7593375B2Active Publication Date: 2024-12-03TOYO INK MFG CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2022088202
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-05-31
Publication Date
2024-12-03
Estimated Expiration
2042-05-31

AI Technical Summary

Technical Problem

Existing cell culture methods using established cell lines and hepatocytes derived from human iPS cells struggle to induce sufficient activity of drug-metabolizing enzymes like CYP, and current additives fail to significantly enhance the expression and activity of drug metabolism-related molecules, particularly CYP3A, while maintaining low cytotoxicity.

Method used

A cell culture medium additive containing a vinyl polymer with specific structural units, such as betaine and amine oxide structures, is used to enhance the expression and activity of drug metabolism-related molecules, with a mass average molecular weight between 600 and 2000, and a concentration of 1% to 4% by mass in the medium.

Benefits of technology

The vinyl polymer additive exhibits low cytotoxicity and effectively induces the expression and activity of drug metabolism-related molecules, improving the accuracy of drug screening and predicting in vivo efficacy and side effects, while being stably supplied with minimal lot variations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593375000001
    Figure 0007593375000001
  • Figure 0007593375000002
    Figure 0007593375000002
  • Figure 0007593375000003
    Figure 0007593375000003
Patent Text Reader

Abstract

To provide a cell additive with low cytotoxicity and the excellent induction of drug metabolism-related molecule expression and activity; to provide a cell culture medium containing the additive; and to provide a cell culture method using the additive.SOLUTION: Provided is a cell culture medium additive, containing a vinyl polymer (V) having at least any one structural unit among the structural units represented by general formulas (1) to (6), the vinyl polymer (V) having a mass average molecular weight of 600 or more and less than 2000. Provided is a cell culture medium containing the cell culture medium additive. The cell culture medium has a concentration of the vinyl polymer (V) in the medium is greater than 1 mass% and not more than 4 mass%.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a cell culture medium additive capable of inducing drug metabolism-related molecules. [Background technology]

[0002] It is very important to clarify drug interactions caused by drug-metabolizing enzymes / transporters in drug screening. Among them, cytochrome P450 (CYP) is a drug-metabolizing enzyme that is mainly present in the liver in humans and is involved in the detoxification and decomposition of substances. In particular, CYP3A is a major molecular species and is involved in the metabolism of about 50% of commercially available drugs (Non-Patent Document 1). Therefore, in drug development, an in vitro evaluation system using cultured hepatocytes with a certain level of drug-metabolizing enzyme activity is required. However, the problem with primary human hepatocytes, which are ideal as a hepatocyte source, is that the activity of drug-metabolizing enzymes varies greatly from lot to lot, and they are very expensive due to limited supply.

[0003] Therefore, cell lines and, in recent years, human iPS cell-derived hepatocytes have been used as alternative cell sources to primary hepatocytes. Cell lines have high proliferation potential and can be supplied stably, but compared to primary hepatocytes, they have extremely low expression of drug metabolism-related genes, including CYP. In addition, various protocols for hepatocyte differentiation from iPS cells have been reported, and although they have succeeded in obtaining hepatocytes with major liver functions, these functions are significantly lower than those of primary hepatocytes, and from the perspective of pharmaceutical development, improvements are required to ensure sufficient drug-metabolizing enzyme activity.

[0004] In order to solve the above problems, many studies have been conducted on the optimization of culture conditions and culture methods. For example, it has been reported that DMSO treatment and confluent culture improve CYP gene expression and activity (Non-Patent Documents 2 and 3). Patent Document 1 reports a method of inducing CYP3A and CYP1A by combining multiple low molecular weight compounds. Furthermore, Patent Document 2 shows that adding a plant extract to a culture medium activates the nuclear receptor PXR for CYP3A, improving CYP activity. However, it has only been shown that the activity of CYP is increased by the above method, and other drug-metabolizing enzymes / transporters have not been verified. In addition, there have been no reports of a significant increase in the activity of drug-metabolizing enzymes by synthetic polymers.

[0005] Therefore, the present invention provides a cell culture medium additive that can induce the expression and activity of drug metabolism-related molecules more potently than the prior art. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2010-111587 A [Patent Document 2] JP 2016-67218 A [Non-patent literature]

[0007] [Non-Patent Document 1] LC Wienkers, et al, Nat. Rev. Srug Discov., 4:825-833, 2005 [Non-Patent Document 2] S. Choi, et al, Xenobiotica, 39(3):205-217, 2009 [Non-Patent Document 3] L. Sivertsson, et al, Drug Metab. Dispos., 38:995-1002, 2010 Summary of the Invention [Problem to be solved by the invention]

[0008] An objective of the present invention is to provide a cell additive that has low cytotoxicity and exhibits excellent induction of the expression and activity of drug metabolism-related molecules, a cell medium containing the additive, and a cell culture method using the additive. [Means for solving the problem]

[0009] That is, the present invention relates to a cell culture medium additive comprising a vinyl polymer (V) having at least one structural unit among the structural units represented by the following general formulas (1) to (6) and having a mass average molecular weight of 600 or more and less than 2,000: General formula (1) [ka] General formula (2) [ka] General formula (3) [ka] General formula (4) [ka] General formula (5) [ka] General formula (6) [ka] (In the formula, R2, R 16 each independently represents an alkylene group having 1 to 6 carbon atoms, R3, R4, R 17 , R 18 each independently represents an alkyl group having 1 to 4 carbon atoms, R5 represents an alkylene group having 1 to 4 carbon atoms; X represents an oxygen atom or NH-; Y is COO - or SO3 - represents R7, R 20 each independently represents a hydrogen atom or a methyl group; R8 represents an alkylene group having 1 to 6 carbon atoms or a hydroxyalkylene group having 1 to 6 carbon atoms; R9~R 13 Four of the groups are independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R 13 one of the groups represents a bonding site with the main chain of the vinyl polymer, R 21 ~R 25 Four of the groups are independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R 21 ~R 25 one of the groups represents a bonding site with the main chain of the vinyl polymer, R 14 represents an alkylene group having 1 to 6 carbon atoms or a hydroxyalkylene group having 1 to 6 carbon atoms, * indicates the bonding position with the main chain of the vinyl polymer.)

[0010] The present invention also relates to a cell culture medium comprising the cell culture medium additive described above.

[0011] The present invention also relates to the above cell culture medium, wherein the concentration of the vinyl polymer (V) in the medium is more than 1% by mass and not more than 4% by mass.

[0012] The present invention also relates to a cell culture method, which comprises culturing cells in the above-mentioned cell culture medium. Effect of the Invention

[0013] The present invention makes it possible to provide a cell additive that has low cytotoxicity and exhibits excellent induction of the expression and activity of drug metabolism-related molecules, a cell medium containing said additive, and a cell culture method using said additive. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The cell culture medium additive of the present invention is characterized by containing a vinyl polymer (V) having a mass average molecular weight of 600 or more and less than 2,000.

[0015] The vinyl polymer (V) has at least one structural unit selected from the betaine structure and amine oxide structure represented by the above general formulae (1) to (6) in its side chain. The content of at least one structural unit selected from the betaine structure and amine oxide structure represented by the following general formulae (1) to (6) is preferably 30 to 95% by mass, more preferably 40 to 80% by mass, based on 100% by mass of the total monomer units constituting the vinyl polymer (V). When the content is within the above range, the solubility in water is improved. Hereinafter, among the vinyl polymers (V), a vinyl polymer having at least one structural unit of the betaine structure represented by the above general formulas (1) to (3) in a side chain is referred to as a vinyl polymer having a betaine structure (A), and a vinyl polymer having at least one structural unit of the amine oxide structure represented by the above general formulas (4) to (6) in a side chain is referred to as a vinyl polymer having an amine oxide structure (B). These vinyl polymers may be simply referred to as vinyl polymer (A) and vinyl polymer (B), but these terms have the same meaning.

[0016] <Vinyl polymer (A) having a betaine structure> The vinyl polymer (A) having a betaine structure is preferably obtained by the following method. That is, (1) Monomers (a1) to (a3) ​​represented by the following general formulas (7) to (9) are copolymerized with other monomers as required. The resulting copolymer is called vinyl polymer (A1). Or, (2) Monomers (a4) to (a6) represented by the following general formulas (10) to (12) are copolymerized with other monomers as necessary, and the moieties derived from the monomers (a4) to (a6) in the obtained copolymer are reacted with a betaining agent described below. The obtained reaction product has a betaine structure like the copolymer using the monomers (a1) to (a3), and is called vinyl polymer (A2).

[0017] General formula (7)(a1) [ka] General formula (8)(a2) [ka] General formula (9)(a3) [ka] General formula (10)(a4) [ka] General formula (11)(a5) [ka] General formula (12)(a6) [ka]

[0018] (In the formula, R1 is a hydrogen atom or a methyl group; R6 represents a hydrogen atom or a methyl group; ** indicates the reaction site with the betaine agent. The other symbols are the same as in general formulas (1) to (3). <Vinyl polymer (A1)> As described above, the vinyl polymer (A1) is a copolymer having monomers (a1) to (a3) ​​represented by the general formulas (7) to (9) as structural units of the copolymer. By using the monomers (a1) to (a3), a betaine structure can be introduced into the side chain of the vinyl polymer.

[0019] <Monomer (a1)> As represented by the general formula (7), the monomer (a1) has one ethylenically unsaturated group and a betaine structure in one molecule. Examples of such monomers include N-(meth)acryloyloxymethyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxyethyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxypropyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxybutyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxymethyl-N,N-diethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxyethyl-N,N-diethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxypropyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxybutyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxymethyl-N,N-diethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxypropyl-N,N-diethylammonium methyl-α-carboxybetaine, N-(meth)acryloyloxybutyl-N ,N-diethylammonium methyl-α-carboxybetaine, etc. N-(meth)acryloyloxyalkyl-N,N-dialkylammonium alkyl-α-carboxybetaine;N-(meth)acrylamidopropyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acrylamidopropyl-N,N-diethylammonium methyl-α-carboxybetaine, etc. N-(meth)acrylamidoalkyl-N,N-dialkylammonium alkyl-α-carboxybetaine;N-(meth)acrylamidopropyl-N,N-dimethylammonium methyl-α-carboxybetaine, N-(meth)acrylamidopropyl-N,N-diethylammonium methyl-α-carboxybetaine, etc. N-(meth)acrylamidoalkyl-N,N-dialkylammonium alkyl-α-carboxybetaine;N-(meth)acryloyloxymethyl-N,N-dimethylammonium methyl-α-sulfobetaine, N-(meth)acryloyloxymethyl-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxymethyl-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxymethyl-N,N-dimethylammonium butyl-α-sulfobetaine, N-(meth)acryloyloxyethyl-N,N-dimethylammonium methyl-α-sulfobetaine, N-(meth)acryloyloxyethyl-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxyethyl-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxyethyl-N,N-dimethylammonium butyl-α-sulfobetaine, N-(meth)acryloyloxypropyl-N,N-dimethyl Ammonium methyl-α-sulfobetaine, N-(meth)acryloyloxypropyl-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxypropyl-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxypropyl-N,N-dimethylammonium butyl-α-sulfobetaine, N-(meth)acryloyloxybutyl-N,N-dimethylammonium methyl-α-sulfobetaine, N-(meth)acryloyloxybutyl-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxybutyl-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxybutyl-N,N-dimethylammonium butyl-α-sulfobetaine, and other N-(meth)acryloyloxyalkyl-N,N-dimethylammonium alkyl-α-sulfobetaines;N-(meth)acryloyloxymethoxymethoxy-N,N-dimethylammonium methyl-α-sulfobetaine, N-(meth)acryloyloxymethoxymethoxy-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxymethoxymethoxy-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxymethoxymethoxy-N,N-dimethylammonium butyl-α-sulfobetaine, N-(meth)acryloyloxyethoxy N-(meth)acryloyloxyethoxyethoxy-N,N-dimethylammonium methyl-α-sulfobetaine, N-(meth)acryloyloxyethoxyethoxy-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxyethoxyethoxy-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxyethoxyethoxy-N,N-dimethylammonium butyl-α-sulfobetaine, N-(meth)acryloyloxypropoxypropoxy-N,N-dimethyl N-(meth)acryloyloxypropoxypropoxy-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxypropoxypropoxy-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxypropoxypropoxy-N,N-dimethylammonium butyl-α-sulfobetaine, N-(meth)acryloyloxybutoxybutoxy-N,N-dimethylammonium methyl- α-sulfobetaine, N-(meth)acryloyloxybutoxybutoxy-N,N-dimethylammonium ethyl-α-sulfobetaine, N-(meth)acryloyloxybutoxybutoxy-N,N-dimethylammonium propyl-α-sulfobetaine, N-(meth)acryloyloxybutoxybutoxy-N,N-dimethylammonium butyl-α-sulfobetaine, and other N-(meth)acryloyloxyalkoxyanerkoxy-N,N-dimethylammonium alkyl-α-sulfobetaines;Examples of the N-(meth)acrylamidoalkyl-N,N-dialkylammonium alkyl-α-sulfobetaines include N-(meth)acrylamidopropyl-N,N-dimethylammonium propyl-α-sulfobetaine and N-(meth)acrylamidopropyl-N,N-dimethylammonium butyl-α-sulfobetaine.

[0020] <Monomer (a2)> As shown in general formula (8), the monomer (a2) also has one ethylenically unsaturated group and a betaine structure in one molecule. Examples of such monomers include 1-vinyl-2-alkyl-3-(4-sulfoalkyl)imidazolium inner salts such as 1-vinyl-3-(3-sulfopropyl)imidazolium inner salt, 1-vinyl-3-(3-sulfobutyl)imidazolium inner salt, 1-vinyl-2-methyl-3-(3-sulfopropyl)imidazolium inner salt, and 1-vinyl-2-methyl-3-(4-sulfobutyl)imidazolium inner salt.

[0021] <Monomer (a3)> As represented by the general formula (9), the monomer (a3) ​​also has one ethylenically unsaturated group and a betaine structure in one molecule. Examples of such monomers include 2-vinyl-1-(3-sulfoalkyl)pyridinium inner salts such as 2-vinyl-1-(3-sulfopropyl)pyridinium inner salt and 2-vinyl-1-(3-sulfobutyl)pyridinium inner salt; and 4-vinyl-1-(3-sulfoalkyl)pyridinium inner salts such as 4-vinyl-1-(3-sulfopropyl)pyridinium inner salt and 4-vinyl-1-(3-sulfobutyl)pyridinium inner salt.

[0022] <Vinyl polymer (A2)> As described above, the vinyl polymer (A) in the present invention does not necessarily have to be a copolymer in which the monomers (a1) to (a3) ​​themselves are copolymerized, and can be obtained via the following steps. That is, it can be obtained by copolymerizing at least one of the monomers (a4) to (a6) represented by the general formulas (10) to (12), which can be called the precursors of the monomers (a1) to (a3), with other monomers as necessary, and reacting at least a part of the nitrogens represented by ** in the obtained copolymer with the betaining agent (D). The obtained vinyl polymer (A2) has a betaine structure in the side chain. It is preferable to use the betaining agent (D) so as to betaine all of the monomers (a4) to (a6).

[0023] Examples of such monomers (a4) include N-(meth)acryloyloxymethyl-N,N-dimethylamine, N-(meth)acryloyloxyethyl-N,N-dimethylamine, N-(meth)acryloyloxypropyl-N,N-dimethylamine, N-(meth)acryloyloxybutyl-N,N-dimethylamine, N-(meth)acryloyloxymethyl-N,N-diethylamine, N-(meth)acryloyloxyethyl-N,N-diethylamine, N-(meth)acryloyloxypropyl-N,N-diethylamine, N-(meth)acryloyloxybutyl-N,N-diethylamine, N-(meth)acryloyloxyalkyl-N,N-dialkylamines such as; N-(meth)acrylamidopropyl-N,N-dimethylamine, N-(meth)acrylamidopropyl-N,N-diethylamine, N-(meth)acrylamidoalkyl-N,N-dialkylamines such as; N-(meth)acryloyloxymethoxymethoxy-N,N-dimethylamine, N-(meth)acryloyloxyethoxyethoxy-N,N-dimethylamine, N-(meth)acryloyloxypropoxypropoxy-N,N-dimethylamine, N-(meth)acryloyloxybutoxybutoxy-N,N-dimethylamine, and N-(meth)acryloyloxyalkoxyanelkoxy-N,N-dimethylamines such as these.

[0024] Examples of such monomers (a5) include Examples of the vinyl imidazole include 1-vinylimidazole, 2-methyl-1-vinylimidazole, 4-methyl-1-vinylimidazole, 5-methyl-1-vinylimidazole, 2-lauryl-1-vinylimidazole, and 4-(t-butyl)-1-vinylimidazole.

[0025] Examples of such monomers (a6) include 2-vinylpyridine, 3-vinylpyridine, 4-vinylpyridine, 2-methyl-3-vinylpyridine, 2-methyl-4-vinylpyridine, 3-methyl-4-vinylpyridine, 2-methyl-5-vinylpyridine, 3-methyl-5-vinylpyridine, 4-methyl-5-vinylpyridine, 2-lauryl-4-vinylpyridine, 2-lauryl-5-vinylpyridine, 2-(t-butyl)-4-vinylpyridine, and 2-(t-butyl)-5-vinylpyridine.

[0026] <Betaine agent (D)> The betaining agent (D) is selected from the group consisting of cyclic sulfonate (D1), ω-halogenated alkylsulfonate metal salt (D2), cyclic carboxylate (D3) and ω-halogenated alkylcarboxylate metal salt (D4). This is a group of compounds used to sulfobetaine or carbobetaine the nitrogen represented by ** in the monomers (a4) to (a6) represented by the general formulas (7) to (9) after polymerization.

[0027] Examples of such cyclic sulfonic acid esters (D1) include 1,2-ethane sultone, 1,3-propane sultone, and 1,4-butane sultone.

[0028] Examples of such ω-halogenated alkylsulfonic acid metal salts (D2) include sodium 2-chloroethanesulfonate, sodium 2-bromoethanesulfonate, sodium 3-chloropropanesulfonate, sodium 3-bromopropanesulfonate, sodium 4-chlorobutanesulfonate, and sodium 4-bromobutanesulfonate.

[0029] Examples of such cyclic carboxylates (D3) include β-propiolactone, γ-butyrolactone, and δ-valerolactone.

[0030] Examples of such ω-halogenated alkyl carboxylate metal salts (D4) include sodium 2-chloroacetate, sodium 2-bromoacetate, sodium 3-chloropropionate, sodium 3-bromopropionate, sodium 4-chlorobutyrate, sodium 4-bromobutyrate, sodium 5-chloropentanoate, and sodium 5-bromopentanoate.

[0031] <Vinyl polymer (B) having an amine oxide structure> The vinyl polymer (B) having an amine oxide structure is It is preferable to obtain it by the following two methods. That is, (1) A monomer having an amine oxide group is copolymerized with other monomers as required. (B1) or, (2) After obtaining a polymer having a tertiary amino group, the tertiary amino group is reacted with an oxidizing agent (hereinafter also referred to as an oxidizing agent) (E) described later. The resulting reaction product has an amine oxide structure like (B1), and is called a vinyl polymer (B2). In addition, the introduction of an amine oxide structure by reacting a tertiary amino group with an oxidizing agent is also called "oxidization."

[0032] <Tertiary amino group-containing monomer (b)> Among the tertiary amino group-containing monomers serving as precursors before oxidation, those for forming the structure of general formula (4) include, for example, those described above as monomer (a4).

[0033] Examples of the monomer for forming the structure of general formula (5) include those described above as monomer (a5).

[0034] Examples of the monomer for forming the structure of general formula (6) include those described above as monomer (a6).

[0035] <Oxidation> The tertiary amino group can be oxidized by adding an oxidizing agent to a solution containing a tertiary amino group-containing monomer or a polymer having a tertiary amino group and reacting the mixture at a temperature in the range of 20°C to 100°C for 0.1 to 100 hours, preferably 1 to 50 hours.

[0036] <Oxidizing agent (E)> As the oxidizing agent, an oxidizing agent such as peroxide or ozone is used. Examples of peroxides include hydrogen peroxide, ammonium persulfate, sodium persulfate, peracetic acid, metachloroperbenzoic acid, benzoyl peroxide, t-butyl hydroperoxide, etc., and hydrogen peroxide is preferred and is usually used in the form of an aqueous solution. Although to different degrees, peroxides also function as radical generators, so in the case of vinyl polymers that use tertiary amino group-containing unsaturated monomers as essential raw materials, it is preferable to oxidize them after polymerization. Generally, the amount of the oxidizing agent used is 0.2 to 3 molar equivalents, more preferably 0.5 to 2 molar equivalents, relative to the oxidizable functional group, ie, the tertiary amino group.

[0037] <Monomer (c)> When obtaining the vinyl polymer (V), a monomer (c) other than the monomers (a1) to (a3) ​​and (b) can also be used.

[0038] Examples of the monomer (c) include Alkyl ester (meth)acrylates such as methyl methacrylate, ethyl (meth)acrylate, propyl (meth)acrylate, n-butyl (meth)acrylate, pentyl (meth)acrylate, heptyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, octyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate, dodecyl (meth)acrylate, lauryl (meth)acrylate, stearyl (meth)acrylate, isostearyl (meth)acrylate, behenyl (meth)acrylate, cyclohexyl (meth)acrylate, and isobornyl (meth)acrylate; Aromatic ester (meth)acrylates such as phenyl (meth)acrylate, benzyl (meth)acrylate, and phenoxyethyl (meth)acrylate; Examples of the aromatic vinyl monomer include styrene, α-methylstyrene, 2-methylstyrene, chlorostyrene, allylbenzene, and ethynylbenzene. These may be used alone or in combination of two or more kinds.

[0039] As the monomer (c), a monomer (c1) having a partition coefficient LogP of 0.8 to 10 can be used, and the vinyl polymer (V) preferably contains a structural unit derived from the monomer (c1) having a partition coefficient LogP of 0.8 to 10. By introducing a structural unit derived from the monomer (c1), the polarity can be more appropriately controlled, the hydrophobic interaction with cells can be controlled, and effects including the antibody productivity of cells can be maximized.

[0040] The partition coefficient LogP is a numerical value that indicates the properties of a chemical substance, and is a constant value that does not depend on the amount added. It is the common logarithm of the concentration of each phase when the substance is in equilibrium in a mixture of water and 1-octanol, where the aqueous phase and the octanol phase are in contact with each other. When LogP is large, the substance tends to be relatively more hydrophobic, and when LogP is small, the substance tends to be relatively more hydrophilic.

[0041] LogP can generally be measured by the flask shaking method described in JIS Japanese Industrial Standards Z7260-107 (2000). LogP can also be estimated by computational chemistry methods or empirical methods instead of actual measurement. Known methods and software can be used to calculate LogP, but in the present invention, LogP is calculated using a program built into CambridgeSoft's system: ChemdrawPro11.0.

[0042] The content of the structural unit derived from the monomer (c1) is preferably 5 to 70% by mass, more preferably 10 to 65% by mass, and even more preferably 20 to 60% by mass, based on the total 100% by mass of the monomer units constituting the vinyl polymer (V). When the content is 5% by mass or more, the amounts of the monomers (a1) to (a3) ​​and (b) become relatively small, and the water solubility of the vinyl polymer (V) can be set within an appropriate range. When the content is 70% by mass or less, the hydrophobic interaction with cells can be appropriately suppressed.

[0043] As the monomer (c), a monomer (c2) having a partition coefficient LogP outside the range of 0.8 to 10 can also be used. When using a monomer (c2) having a partition coefficient LogP outside the range of 0.8 to 10, the content thereof is preferably 0 to 65 mass%, more preferably 0 to 40 mass%, and even more preferably 0 to 20 mass%, based on 100 mass% of the total monomer units constituting the vinyl polymer (V). This is because the functions of the betaine structure and / or amine oxide structure are more easily exhibited.

[0044] In the present invention, a chain transfer agent may be used to control the molecular weight and molecular weight distribution of the vinyl polymer. The chain transfer agent is not particularly limited, and for example, compounds having a thiol group or a hydroxyl group are generally known. Examples of compounds having a thiol group include mercaptans such as lauryl mercaptan, 2-mercaptoethyl alcohol, dodecyl mercaptan, and mercaptosuccinic acid; alkyl mercaptopropionates such as n-butyl mercaptopropionate and octyl mercaptopropionate; and alkoxyalkyl mercaptopropionates such as methoxybutyl mercaptopropionate. In addition, alcohols such as methyl alcohol, n-propyl alcohol, isopropyl alcohol (IPA), t-butyl alcohol, and benzyl alcohol may also be used. The chain transfer agent may be used alone or in combination of two or more kinds.

[0045] <Mass average molecular weight (Mw)> The weight average molecular weight of the vinyl polymer (V) is 600 or more and less than 2000. The weight average molecular weight is preferably 700-1950, and more preferably 800-1900. When the mass average molecular weight of the vinyl polymer (V) is within the above range, the interaction with cells is enhanced, and the induction ability of drug metabolism-related molecules can be improved.

[0046] The mass average molecular weight of the vinyl polymer (V) was measured by gel permeation chromatography (GPC) in terms of standard pullulan. The following condition 1 was used as the measuring device and conditions. For other matters, JIS K7252-1-4:2008 was referenced. When it was difficult to measure the molecular weight under condition 1, the following condition 2 was used as the basis, and when it was difficult to measure the molecular weight of the vinyl polymer, the mass average molecular weight of the betaine or amine oxide precursor polymer was used as the mass average molecular weight of the polymer. The mass average molecular weight of the precursor polymer was measured by gel permeation chromatography (GPC) in terms of standard polystyrene.

[0047] (Condition 1) Column: OHpak SB-G, Three OHpak SB-806M HQs and OHpak SB-802.5 HQ connected together. Carrier: 1 / 15 mol / L pH7.0 phosphate buffer (Phosphate buffer powder 1 / 15 mol / L pH 7.0 (FUJIFILM Wako Pure Chemical Industries, Ltd.) dissolved in 1 L of ion-exchanged water) Carrier flow rate: 1.0mL / min Sample concentration: 0.5% by mass Detector: RI (refractive index) detector Injection volume: 0.1mL (Condition 2) Column: TOSOHTSKgelSuperAW4000, TOSOHTSKgelSuperAW3000 and TOSO HTS Kgel Super AW2500 connected together. Carrier: A mixture of N,N-dimethylformamide (1 L), triethylamine (3.04 g), and LiBr (0.87 g). Measurement temperature: 40℃ Carrier flow rate: 0.6mL / min

[0048] The obtained polymer solution can be used as it is, but can be purified as necessary. The purification method is not particularly limited, but examples thereof include reprecipitation, ultrafiltration, dialysis, ion exchange resin treatment, etc. Each method may be performed alone or in combination.

[0049] <Cell Culture Media> As the cell culture medium to which the cell additive of the present invention is added, a conventionally known cell culture medium can be used, for example, various commercially available media (αMEM, MEM, DMEM, IMDEM, RPMI1640, DMEM / F12, etc.) and combinations thereof. In the above cell culture medium, the concentration of the vinyl polymer (V) in the total mass of the medium is preferably more than 1% by mass and not more than 4% by mass, more preferably not more than 3.5% by mass, even more preferably not more than 3% by mass, and particularly preferably not more than 2.5% by mass. By having the concentration of the vinyl polymer (V) in the cell culture medium within the above range, cytotoxicity is reduced and an excellent effect of enhancing the activity of drug metabolism-related molecules is exhibited.

[0050] It is preferable to add various growth factors (e.g., epidermal growth factor, insulin-like growth factor, nerve growth factor, hepatocyte growth factor, vascular endothelial growth factor, basic fibroblast growth factor, transferrin, steroid hormones, 2-mercaptoethanol, etc.), various animal sera (e.g., fetal bovine serum (FBS) and bovine serum), serum substitutes, etc. to the cell culture medium as necessary.

[0051] <cell> Examples of cells cultured using the cell medium additive of the present invention include cells in tissues in vivo where drug-metabolizing enzyme induction occurs, and examples of tissues from which they are derived include liver, small intestine, etc. The cells are preferably organisms for which drug-metabolizing enzyme induction is to be tested, and examples of such organisms include mammals such as humans and mice. Examples of cells capable of producing drug-metabolizing enzymes that can be cultured using the cell medium additive of the present invention include primary hepatocytes / intestinal cells collected from animal tissues, hepatocytes / intestinal cells induced to differentiate from stem cells such as ES cells, iPS cells, and mesenchymal stem cells. Examples of cell lines derived from liver cancer include HepG2 cells, HuH-7 cells, HLE cells, HLF cells, and HepaRG cells. Examples of human colon cancer cell lines include Caco-2, HT-29, SW 1116, T84, IEC-18, and IEC-6 cells.

[0052] When culturing using the cell medium additive of the present invention, a container or device that is usually used for culturing can be used, such as a multi-well plate, a petri dish, a culture flask, a spinner flask, a jar fermenter, a fermenter, a roller bottle, a hollow fiber, or a microcarrier.

[0053] The culture conditions when culturing using the cell medium additive of the present invention may be the same as those for ordinary animal cells, for example, a 5% by volume CO2 atmosphere at a temperature of 37°C.

[0054] When culturing using the cell medium additive of the present invention, cells can be harvested from the culture medium by, for example, directly centrifuging or filtering the culture medium in the case of suspended cells, while in the case of adherent cells, cells can be suspended by adding, for example, 0.25% trypsin-0.02% EDTA solution, and then harvested by centrifugation or filtration.

[0055] <Drug Metabolizing Enzymes> The drug metabolizing enzymes produced are not particularly limited, and examples thereof include alcohol dehydrogenase, aldehyde dehydrogenase, glutathione peroxidase, superoxide dismutase, monoamine oxidase, diamine oxidase, epoxide hydrolase, esterase, amidase, UDP-glucuronosyltransferase, glutathione S-transferase, γ-glutamyltranspeptidase, acetyltransferase, sulfotransferase, and CYP.

[0056] <Functional evaluation of molecules related to drug metabolism> The expression level or activity of a drug metabolism-related molecule can be measured using any method known to those skilled in the art. For example, the expression level of CYP can be measured using well-known techniques such as quantitative PCR, Western blotting, flow cytometry (FACS), ELISA, and immunohistochemistry. CYP enzyme activity can be evaluated by adding a CYP substrate to cultured hepatocytes and measuring the amount of the substrate converted by CYP (CYP enzyme activity), and in this case, it can be measured using, for example, liquid chromatography mass spectrometry (LC / MS / MS). In addition, when evaluating the relative ratio (fold-change) of CYP enzyme activity, it can also be performed using a commercially available kit that can be used to measure CYP enzyme activity. For example, in the case of CYP3A4, Promega's P450-GloTM CYP3A4 Assay with Luciferin-IPA can be used. Known methods and kits may be used depending on the type of CYP to be measured. EXAMPLES

[0057] The present invention will be described in more detail below with reference to examples, but the following examples are not intended to limit the scope of the invention. In the examples and comparative examples, "parts" and "%" represent "parts by mass" and "% by mass", "mol" represents the amount of a substance, and "mol%" represents the proportion of the amount of a substance in the total monomers.

[0058] <Synthesis of betaine monomer> The N-methacryloyloxyethyl-N,N-dimethylammonium butyl-α-sulfobetaine used in the synthesis of the vinyl polymer was synthesized with reference to Japanese Patent No. 5690645. Similarly, the N-methacryloyloxyethyl-N,N-dimethylammonium methyl-α-carbobetaine was synthesized with reference to Japanese Patent No. 3878315, and the 1-vinyl-3-(3-sulfopropyl)imidazolium inner salt and 2-vinyl-1-(3-sulfopropyl)pyridinium inner salt were synthesized with reference to Japanese Patent No. 3584998.

[0059] <Synthesis of vinyl polymers having betaine structures> [Production Example 1] In a reaction vessel equipped with a stirrer, a thermometer, a dropping funnel, and a reflux condenser, 150 parts of isopropanol was charged, the internal temperature was raised to 75°C, and the atmosphere was fully replaced with nitrogen. Separately prepared 10 parts of 2,2'-azodiisobutyronitrile and 100 parts of N-methacryloyloxyethyl-N,N-dimethylammonium butyl-α-sulfobetaine as monomer (a1) were added dropwise for 3 hours while maintaining the internal temperature at 75°C, and stirring was continued for another 2 hours. After confirming that the conversion rate exceeded 98% by measuring the solid content, the mixture was cooled and taken out. Thereafter, the isopropanol was completely evaporated in an oven to obtain a vinyl polymer (A1).

[0060] [Production Examples 2 to 11, Comparative Production Example 1] Using the composition shown in Table 1, a vinyl polymer was synthesized in the same manner as in Production Example 1.

[0061] [Table 1]

[0062] The abbreviations in Table 1 are as follows. DMBS: N-methacryloyloxyethyl-N,N-dimethylammonium butyl-α-sulfobetaine DMMC: N-methacryloyloxyethyl-N,N-dimethylammonium methyl-α-carbobetaine VSPI: 1-vinyl-3-(3-sulfopropyl)imidazolium inner salt VSPP: 2-vinyl-1-(3-sulfopropyl)pyridinium inner salt BMA: Butyl methacrylate LMA: Lauryl methacrylate St: styrene HEA: 2-hydroxyethyl acrylate AA: Acrylic acid

[0063] The partition coefficients LogP of the monomers (c) shown in Table 1 are shown below. LogP was determined by a program incorporated in the CambridgeSoft system: ChemdrawPro11.0. BMA: LogP = 2.23 LMA: LogP = 5.57 St: LogP = 2.67 HEA: LogP = 0.48 AA: LogP = 0.38

[0064] <Synthesis of vinyl polymer (A2) having a betaine structure> [Production Example 12] A reaction vessel equipped with a stirrer, a thermometer, a dropping funnel, and a reflux condenser was charged with 150 parts of isopropanol, and the internal temperature was raised to 75° C. and the atmosphere was thoroughly replaced with nitrogen. A mixture of 10 parts of 2,2'-azodiisobutyronitrile, 60 parts of N-methacryloyloxyethyl-N,N-dimethylamine as monomer (a4), 30 parts of butyl methacrylate as monomer (c), and 10 parts of 2-hydroxyethyl acrylate, which had been separately prepared, was added dropwise for 3 hours while maintaining the internal temperature at 75° C., and stirring was continued for another 2 hours to obtain a vinyl copolymer. After confirming that the conversion rate exceeded 98% by solid content measurement, 47 parts of 1,4-butane sultone as a betaine agent (D) and 200 parts of ion-exchanged water were added, and stirring was continued for another 20 hours while distilling off isopropanol. Next, the reaction product was cooled and taken out, and the solvent was completely evaporated in an oven to obtain a vinyl polymer (A2) of Production Example 12.

[0065] As shown in the reaction scheme below, a structure derived from N-methacryloyloxyethyl-N,N-dimethylammonium butyl-α-sulfobetaine, which is a type of monomer (a1), can be introduced into the side chain of a vinyl polymer by the ring-opening reaction of 1,4-butane sultone.

[0066] [ka]

[0067] [Manufacturing Examples 13-16] Using the compositions shown in Table 2, synthesis was carried out in the same manner as in Production Example 12, to obtain vinyl polymers (A2) of Production Examples 13 to 16.

[0068] [Table 2]

[0069] The abbreviations in Table 2 are as follows. DM: N-methacryloyloxyethyl-N,N-dimethylamine VI: 1-Vinylimidazole VP: 2-vinylpyridine DEAA: Diethylacrylamide BS: 1,4-butane sultone PS: 1,3-propane sultone SBS: Sodium 4-bromobutanesulfonate PL: β-propiolactone SC: Sodium chloroacetate

[0070] The partition coefficients LogP of the monomers (c) shown in Table 2 are shown below. DEAA: LogP = 0.2

[0071] [Production Example 17] <Synthesis of vinyl polymer (B) having an amine oxide structure> In a reaction vessel equipped with a thermometer, a stirrer, a nitrogen inlet tube, a reflux condenser, and a dropping tube, 150 parts by mass of isopropanol was charged as an organic solvent under a nitrogen stream, and heated at 80°C for 30 minutes while stirring. In the dropping tube, 80 parts of N,N-dimethylaminopropylacrylamide as monomers, 20 parts of butyl methacrylate, 10 parts of 2,2'-azodiisobutyronitrile as a polymerization initiator, and 10 parts of isopropanol as a solvent were charged and dropped over 2 hours. After the dropwise addition, the mixture was aged for 6 hours. The reaction was then stopped by cooling to room temperature. Next, 150 parts of isopropanol and 50 parts of 35% hydrogen peroxide solution (equimolar amount to the N,N-dimethylaminopropyl methacrylate used) as an oxidizing agent were added, and the mixture was reacted for 16 hours at 70° C. to oxidize the amino groups. The solvent was then removed with a diaphragm pump to obtain a vinyl polymer (B). [Examples 18-25] Using the composition shown in Table 3, a vinyl polymer (B) was synthesized in the same manner as in Production Example 17.

[0072] [Table 3]

[0073] The abbreviations in Table 3 are as follows. DMAPAA: N,N-dimethylaminopropylacrylamide DEAEMA: N,N-diethylaminoethyl methacrylate BMA: Butyl methacrylate 2EHA: 2-Ethylhexyl acrylate MMA: Methyl methacrylate St: styrene AA: Acrylic acid

[0074] The partition coefficients LogP of the monomers (c) shown in Table 2 are shown below. 2EHA: LogP=3.52

[0075] In addition, 1 g of each of the vinyl polymers obtained in Production Examples 1 to 25 and Comparative Production Example 1 was added to 99 g of ion-exchanged water at 25° C., stirred to dissolve, and then allowed to stand for 24 hours at 25° C. As a result, neither separation nor precipitation was observed in these resins, indicating that they were completely soluble and water-soluble.

[0076] <Preparation of cell culture medium additives> [Examples 1 to 25, Comparative Example 1] The vinyl polymers obtained in the above Production Examples 1 to 25 and Comparative Production Example 1 after evaporation of the solvent were dissolved in phosphate buffered saline (hereinafter, PBS solution) to obtain cell culture medium additives having a concentration of 10% by mass.

[0077] [Comparative Examples 2 and 3] Polyvinyl alcohol (PVA) or polyethylene glycol (PEG) was dissolved in a PBS solution to obtain a cell culture medium additive having a concentration of 10% by mass.

[0078] [Comparative Example 4] Rifampicin was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 20 mM to obtain a cell culture medium additive.

[0079] The obtained cell culture medium additive was evaluated as follows, and the results are shown in Table 5. For the evaluations described below, a predetermined amount of cell medium additive was added to each basal medium to prepare a cell medium composition (hereinafter referred to as medium composition), which was then evaluated at final concentrations of 1.5% by mass and 3% by mass.

[0080] <Cytotoxicity evaluation> The obtained cell medium additive was added to 10% FBS-DMEM medium to the concentration shown in Table 5, and the medium composition was prepared by stirring. Human hepatoma cell line HuH-7 cells were seeded with the medium composition containing the cell medium additive containing a polymer so as to have a concentration of 10,000 cells / mL, and then dispensed into the wells of a 96-well U-bottom microplate so that 100 μL per well was dispensed. Then, the plate was cultured for 3 days in a stationary state in a CO2 incubator (37°C, 5% CO2). After 3 days of culture, 10 μL of WST-8 reagent (manufactured by Dojinsha Research Institute Co., Ltd.) was added to the culture solution containing the hepatocytes, and the culture solution was left stationary for 2 hours in a CO2 incubator (37°C, 5% CO2). After 2 hours, the absorbance at 450 nm was measured using a microplate reader, and the cytotoxicity was evaluated by subtracting the absorbance of the culture solution to which the WST-8 reagent was not added. The results were evaluated as a relative value, assuming that the results when cultured without the addition of a cell culture medium additive containing a polymer were 1. (Evaluation Criteria) ◎: 1.0 or above (Very Good) ○: 0.90 or above and less than 1.0 (Good) ×: Less than 0.90 (Poor)

[0081] <Gene Expression Analysis of Drug Metabolism-Related Molecules by qRT-PCR Method> Cell culture medium additives obtained in 10% FBS-DMEM medium were added to the medium at the concentrations shown in Table 5 and stirred to prepare the medium composition. HuH-7 cells cultured in various media for 3 days were collected, and total RNA was extracted using the RNeasy Micro Kit (manufactured by QIAGEN). cDNA was synthesized from each extracted total RNA by reverse transcription reaction using ReverTra Ace qPCR RT Master Mix (manufactured by TOYOBO). qRT-PCR was performed using the cDNA, TaqMan probe for the target gene, and Taqman fast advanced master mix (manufactured by ThermoFisher). The Taqman probes used for the expression analysis are shown in Table 4 below. Using GAPDH as the reference gene, the relative expression levels of each gene were calculated using the comparative Ct method based on GAPDH. The results were judged as relative values when the performance when cultured without adding the cell culture medium additive was set to 1. (Evaluation Criteria) ◎: 5 or above (Very Good) ○: 1.5 or above and less than 5 (Good) △: 1 or above and less than 1.5 (No Change) ×: Less than 1 (Poor)

[0082]

Table 4

[0083] <Evaluation of Drug Metabolism Enzyme Activity: CYP3A4 Activity> The obtained cell medium additive was added to 10% FBS-DMEM medium to the concentration shown in Table 5, and the medium composition was prepared by stirring. Human liver cancer cell line HuH-7 cells were cultured in a CO2 incubator (37°C, 5% CO2) for 3 days in the medium composition containing the above cell medium additive. After 3 days of culture, the cells were washed with PBS and the DMEM medium was replaced. CYP3A4 activity was measured using P450-GloTM CYP3A4 Assay Kits (Promega), and Luciferin-IPA was used as a CYP3A4 substrate. CYP3A4 activity was measured using a plate reader (Berthold). The amount of DNA in the cell group was also quantified, and the CYP activity per unit DNA amount was calculated. The relative value was determined when the results of culture without adding the cell medium additive containing resin microparticles were set to 1. (Evaluation Criteria) ◎: 5 or more (very good) ○: 1.5 or more and less than 5 (good) △: 1 or more but less than 1.5 (no change) ×: Less than 1 (bad)

[0084] <Excretory activity: Excretion of metabolites of model drugs into the bile canaliculus> The obtained cell medium additive was added to 10% FBS-DMEM medium to the concentration shown in Table 5, and the medium composition was prepared by stirring. Human liver cancer cell line HuH-7 cells were cultured in a CO2 incubator (37°C, 5% CO2) for 3 days in the medium composition containing the above cell medium additive. After 3 days of culture, the cells were washed and removed with PBS, and then a culture solution containing fluorescein diacetate (hereinafter referred to as FD) as a model drug was added and cultured for 60 minutes in a CO2 incubator. FD does not emit fluorescence as it is, but when the ester bond is broken by the esterase activity in the liver cells, green fluorescence of fluorescein (excitation wavelength: 490 nm, fluorescence wavelength: 514 nm) is observed. After removing the culture solution containing FD, the cells were washed with PBS and then observed under a fluorescent microscope. (Evaluation Criteria) ◎: Clear excretion ○: Excretion ×: No excretion

[0085] [Table 5]

[0086] <Result> From the results in Table 5, it was found that the cell culture medium additives of Examples 1 to 25 had low cytotoxicity and showed excellent induction of the expression and activity of drug metabolism-related molecules. On the other hand, the additives of Comparative Examples 1 to 4 were inferior to the cell culture additives of Examples 1 to 25 in both cytotoxicity and the ability to induce the expression and activity of drug metabolism-related genes.

[0087] From the above, the cell medium additive of the present invention can enhance the activity of drug metabolism-related molecules when cells expressing the molecules are cultured using the medium obtained by adding the cell medium additive of the present invention. In addition, since the cell medium additive of the present invention can enhance the activity of drug metabolism-related molecules, it becomes possible to accurately predict the efficacy and side effects of drug candidate compounds in vivo in vitro. In addition, it is expected that adding the cell medium additive of the present invention to established cell lines or iPS cell-derived hepatocytes will lead to the creation of a cell source that has small lot differences and can be stably supplied in drug development. From the above, the present invention can greatly contribute to drug screening in drug development.

Claims

1. A cell culture medium additive comprising a vinyl polymer (V) having at least one structural unit among structural units represented by the following general formulas (1) to (3) and having a mass average molecular weight of 600 or more and less than 2,000: General formula (1) 【Chemistry 1】 General formula (2) 【Chemistry 2】 General formula (3) 【Chemistry 3】 (In the formula, R 2 represents an alkylene group having 1 to 6 carbon atoms; R 3 , R 4 each independently represents an alkyl group having 1 to 4 carbon atoms; R 5 represents an alkylene group having 1 to 4 carbon atoms, X represents an oxygen atom or NH-; Y is -COO - Or S.O. 3 - represents R 7 represents a hydrogen atom or a methyl group; R 8 represents an alkylene group having 1 to 6 carbon atoms or a hydroxyalkylene group having 1 to 6 carbon atoms, R 9 ~R 13 Four of the groups are independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R 9 ~R 13 one of the groups represents a bonding site with the main chain of the vinyl polymer, R 14 represents an alkylene group having 1 to 6 carbon atoms or a hydroxyalkylene group having 1 to 6 carbon atoms; * indicates the bonding position with the main chain of the vinyl polymer.)

2. A cell culture medium comprising the cell culture medium additive according to claim 1.

3. The cell culture medium according to claim 2 , wherein the concentration of the vinyl polymer (V) in the medium is greater than 1% by mass and less than or equal to 4% by mass.

4. A method for culturing cells, comprising culturing cells in the cell culture medium according to claim 2 or 3.

Citation Information

Patent Citations

  • Biomedical material

    JP1986276858A

  • Betaine-type monomer, method for producing the same and polymer thereof

    JP2002003456A

  • PXR-activating agent

    JP2010111587A

  • Cytochrome p450 activity inducing method for human hepatocyte

    JP2016067218A

  • Pellet, sheet, laminate, cylindrical object, bag-like container for cell culture, method for producing laminate and method for producing cylindrical object

    JP2019077786A